in response to the global rise and threat of diabetes.
insulin biosimilars by putting science at the forefront with a goal of
transforming the lives of diabetic patients who needs insulin – we are
driven by simple purpose of “no one should be left behind” because of
We employ a totality approach in our accelerated development of insulin biosimilars, and this is our cornerstone and fundamental principle to achieve our mission. We are focused on our core strengths such as development, scale-up, technology transfer and manufacturing, while trusting our partners for their commercialization capabilities and the simplification of supply chain for diabetes patients.